ABSTRACT
Description: Abciximab is a recombinant chimeric human-murine Fab antibody fragment. It consists of the variable fragments of the murine monoclonal antibody 7E3 combined with constant regions from human-derived light and heavy chains. The Fab fragment is specific for the glycoprotein IIb/IIIa receptor, which is found on human platelets, and binding inhibits platelet aggregation. Abciximab is produced by continuous perfusion culture in a modified murine myeloma Sp2/0 cell line. It is provided as a solution (2 mg/ml) for intravenous injection and infusion.
